ÂÜÀòÂÒÂ×

Dr‭. ‬Izrael Joined Kadimastem in 2009‭. ‬Prior to joining Kadimastem‭, ‬as part of her doctoral work at the Weizmann Institute of Science in the laboratory of Prof‭. ‬Revel‭, ‬Dr‭. ‬Izrael was a central part of the team that invented and developed the technology which became the basis for Kadimastem’s cell therapy product for Amyotrophic Lateral Sclerosis‭ (‬ALS‭) ‬and other neurodegenerative diseases‭. ‬

At Kadimastem she served as‭ ‬the head of the drug screening team‭, ‬based on human oligodendrocytes‭ (‬Myeling forming cells‭), ‬and in 2012‭ ‬was appointed to run‭ ‬the neurodegenerative department at Kadimastem‭, ‬responsible for Kadimastem’s cell product for ALS‭.

‬In 2017‭ ‬she was appointed as VP for Research and Development for ALS and Neurodegenerative Diseases‭.

‬Dr‭.‬‭ ‬Izrael holds a PhD in molecular genetics from the Weizmann Institute of Science and M.Sc‭. ‬in Neurobiology from the Hebrew University of Jerusalem‭. ‬

Dr‭. ‬Izrael has published 16‭ ‬scientific papers and patents in the field of neurobiology and development of technologies based on stem cell derivatives for the treatment of central nervous system disease and drug screening‭.